Search Results

PolarityTE Secures $22.5 Million Financing to Advance SkinTE Phase III Pivotal Study in Diabetic Foot Ulcers

PolarityTE, a clinical-stage biotechnology company developing regenerative tissue products, today announced that it has raised $12.5 million in equity financing from institutional investors and current shareholders.

May 20, 2024

·

2 min read

Drug Development

PolarityTE Announces First Subject Screened in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers

PolarityTE today announced the Screening of the first subject in the Phase III pivotal study evaluating SkinTE in the investigational treatment of Wagner grade 1 diabetic foot ulcers (DFUs), entitled “Closure Obtained with Vascularized Epithelial Regeneration for DFUs with SkinTE II,” or “COVER DFUS II.”

February 26, 2024

·

2 min read

BioMidwest

PolarityTE Announces Entry Into a Letter of Intent For Acquisition of the Company

PolarityTE, Inc. announced that it signed a non-binding letter of intent with Michael Brauser for him to make an offer to acquire 100% of the outstanding equity interests of the Company at a proposed offering price of $1.03 per common share, which would be paid entirely in cash.

December 27, 2022

·

3 min read

Deals

Grander Closes Acquisition of PolarityTE, Inc. Assets

Grander Acquisition LLC, an entity led by Michael Brauser, announced the Company has closed on its acquisition of substantially all of the assets of RegenETP, Inc., a biotechnology company that had been developing regenerative tissue products.

August 22, 2023

·

2 min read

Business

PolarityTE Announces Resignation of Jeff Dyer from its Board of Directors

PolarityTE, Inc. announced that Jeff Dyer, PhD, has decided to resign from its Board of Directors, effective immediately.

September 8, 2022

·

2 min read

Deals

PolarityTE Confirms Receipt of Unsolicited, Non-Binding Offer to Acquire the Company

PolarityTE, Inc. confirmed that on November 1, 2022, it received an unsolicited, non-binding offer from Michael Brauser to acquire all of the outstanding common stock of the Company not owned by him for $1.25 per share in cash.

November 9, 2022

·

2 min read

Business

PolarityTE Reports Third Quarter 2022 Financial Results and Provides Business Update

PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the quarterly period ended September 30, 2022.

November 10, 2022

·

19 min read

Business

PolarityTE to Report Q2 2022 Financial Results on August 11, 2022

PolarityTE, Inc. (NASDAQ: PTE) today announced that it will report results for the quarter ended June 30, 2022 , by press release on Thursday, August 11, 2022, at approximately 4:05 p.m. Eastern Time.

August 1, 2022

·

1 min read

Business

PolarityTE Reports First Quarter 2022 Financial Results and Provides Business Update

PolarityTE to host conference call and webcast today, May 16, 2022 , at 8:30 a.m. ET.

May 16, 2022

·

20 min read

BioMidwest

PolarityTE to Attend H.C. Wainwright Global Investment Conference

PolarityTE, Inc. announced that Richard Hague, Chief Executive Officer, and Nikolai Sopko, MD, PhD, Chief Scientific Officer, will present at the upcoming H.C. Wainwright Global Investment Conference, being held May 23-26, 2022, in Miami and virtually.

May 23, 2022

·

2 min read